Critically examine how the PLI Scheme for Bulk Drugs contributes to supply-chain resilience in critical APIs.

Active Pharmaceutical Ingredients (APIs) and Key Starting Materials are the chemical building blocks of every formulation, yet about two-thirds of India's bulk drug and intermediate imports come from China, mainly for cost reasons [2]. The PLI Scheme for Bulk Drugs (2020, ₹6,940 crore, 41 critical products) was the direct response [1]. It has measurably deepened resilience, but only partially.

Contributions to resilience

• Physical capacity, not announcements: of 48 approved projects, 39 covering 28 APIs/KSMs have been commissioned [1].
• Revival of fermentation-based products: Penicillin-G, Clavulanic Acid and Rifampicin — the base of widely used antibiotics — are again made domestically, cutting exposure to a concentrated import source [1].
• Investment response exceeded commitment: ₹5,210.74 crore realised against ₹4,330 crore committed, with about 5,127 jobs [1].
• Complementary infrastructure: the Scheme for Promotion of Bulk Drug Parks (₹3,000 crore; Himachal Pradesh, Gujarat, Andhra Pradesh; up to ₹1,000 crore each) offers shared utilities that permanently lower production cost [4].

Limitations

• Coverage gap: capacity exists for only 28 of the 41 identified critical products [3]; for the rest, a foreign supply cut would hurt as it did in 2020.
• Dependence shifts upstream: finished drugs can be made here from imported KSMs, so headline output does not prove a secure chain [1], [2].
• Sustainability after the incentive lapses: fermentation needs scale and cheap power; bulk drug exports are only about 15% of scheme sales (₹560.16 crore of ₹3,792.49 crore) [1], signalling limited global cost-competitiveness.
• Fiscal opacity: incentive actually disbursed is not reported, so cost per job or per rupee of output cannot be tested [1].

The scheme has therefore restored genuine capability in the most vulnerable molecules, without yet ending structural import reliance. Completing the Bulk Drug Parks before incentives expire, redesigning support for the uncovered critical products, and publishing disbursement data would convert a subsidy-led revival into durable self-reliance — the essence of Atmanirbhar Bharat and of SDG-3's medicine-security goal.